Loading
A phase 1 trial of SC-102 run by Tianjin ConjuStar Biologics Co., Ltd., now recruiting.
Study of SC-102 in Patients With Advanced Solid Tumors is a phase 1 interventional study registered as NCT06710158 by Tianjin ConjuStar Biologics Co., Ltd., with 120 participants planned, started 2024-12-05. Conditions recorded: Advanced Solid Cancers. Interventions recorded: SC-102.
Shares ConjuStar Biologics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares ConjuStar Biologics and the tag pipeline.
Shares ConjuStar Biologics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/